Connect with us

Business

Biohaven CEO says drug approval is ‘monumental’ for migraine patients – CNBC

“This is going to change the paradigm in which migraine is treated,” Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec…

Published

on

Article feature image
ADVERTISEMENT

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.
The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
United commemorates Juneteenth with a historic all-Black flight crew out of Houston’s Bush Intercontinental Airport – KTRK-TV
Article feature image
Crypto Analyst Predicts Bitcoin Price Will Reach ‘$150,000 by December 15th, 2021’ – CryptoGlobe
Article feature image
Judge Blocks CDC From Enforcing Cruise Ship Coronavirus Rules – HuffPost